Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report
Most cases of acute promyelocytic leukemia (APL) are driven by the PML::RARA fusion gene, which is sensitive to differentiation induction therapy comprising of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Treatment with ATRA plus ATO has achieved remarkable clinical outcome in patients...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1529640/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850193517845938176 |
|---|---|
| author | Xianfeng Ouyang Jianguo Yan Su Hu Wenfeng Zhu Qibao Zhou Fei Hu |
| author_facet | Xianfeng Ouyang Jianguo Yan Su Hu Wenfeng Zhu Qibao Zhou Fei Hu |
| author_sort | Xianfeng Ouyang |
| collection | DOAJ |
| description | Most cases of acute promyelocytic leukemia (APL) are driven by the PML::RARA fusion gene, which is sensitive to differentiation induction therapy comprising of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Treatment with ATRA plus ATO has achieved remarkable clinical outcome in patients with typical APL. However, 5% of patients still died from relapsed/refractory disease, predominantly high-risk APL and variant APL. The diagnosis and treatment of variant APL remain challenging. Here, we report a case of TFG::RARA variant APL recognized by targeted RNA sequencing. The patient achieved a sustained complete response following treatment with venetoclax combined with ATRA. Currently, the overall survival (OS) of the patient has exceeded 30 months, and the progression-free survival (PFS) has reached 29 months. Our results suggest that venetoclax combined with ATRA may be an ideal treatment option for patients with TFG::RARA variant APL. |
| format | Article |
| id | doaj-art-57d92c8242f6423eb9cb4dff530912c7 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-57d92c8242f6423eb9cb4dff530912c72025-08-20T02:14:15ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-05-011510.3389/fonc.2025.15296401529640Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case reportXianfeng Ouyang0Jianguo Yan1Su Hu2Wenfeng Zhu3Qibao Zhou4Fei Hu5Department of Hematology, Jiujiang First People’s Hospital, Jiujiang, Jiangxi, ChinaDepartment of Hematology, Jiujiang First People’s Hospital, Jiujiang, Jiangxi, ChinaDepartment of Hematology, Jiujiang First People’s Hospital, Jiujiang, Jiangxi, ChinaDepartment of Hematology, Jiujiang First People’s Hospital, Jiujiang, Jiangxi, ChinaDepartment of Cardiovascular Medicine, Jiujiang First People’s Hospital, Jiujiang, Jiangxi, ChinaDepartment of Hematology, Jiujiang First People’s Hospital, Jiujiang, Jiangxi, ChinaMost cases of acute promyelocytic leukemia (APL) are driven by the PML::RARA fusion gene, which is sensitive to differentiation induction therapy comprising of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Treatment with ATRA plus ATO has achieved remarkable clinical outcome in patients with typical APL. However, 5% of patients still died from relapsed/refractory disease, predominantly high-risk APL and variant APL. The diagnosis and treatment of variant APL remain challenging. Here, we report a case of TFG::RARA variant APL recognized by targeted RNA sequencing. The patient achieved a sustained complete response following treatment with venetoclax combined with ATRA. Currently, the overall survival (OS) of the patient has exceeded 30 months, and the progression-free survival (PFS) has reached 29 months. Our results suggest that venetoclax combined with ATRA may be an ideal treatment option for patients with TFG::RARA variant APL.https://www.frontiersin.org/articles/10.3389/fonc.2025.1529640/fullacute promyelocytic leukemiavariant APLTFG::RARAvenetoclaxall-trans retinoic acidarsenic trioxide |
| spellingShingle | Xianfeng Ouyang Jianguo Yan Su Hu Wenfeng Zhu Qibao Zhou Fei Hu Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report Frontiers in Oncology acute promyelocytic leukemia variant APL TFG::RARA venetoclax all-trans retinoic acid arsenic trioxide |
| title | Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report |
| title_full | Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report |
| title_fullStr | Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report |
| title_full_unstemmed | Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report |
| title_short | Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report |
| title_sort | venetoclax combined with atra shows promising therapeutic potential for tfg rara variant apl a case report |
| topic | acute promyelocytic leukemia variant APL TFG::RARA venetoclax all-trans retinoic acid arsenic trioxide |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1529640/full |
| work_keys_str_mv | AT xianfengouyang venetoclaxcombinedwithatrashowspromisingtherapeuticpotentialfortfgraravariantaplacasereport AT jianguoyan venetoclaxcombinedwithatrashowspromisingtherapeuticpotentialfortfgraravariantaplacasereport AT suhu venetoclaxcombinedwithatrashowspromisingtherapeuticpotentialfortfgraravariantaplacasereport AT wenfengzhu venetoclaxcombinedwithatrashowspromisingtherapeuticpotentialfortfgraravariantaplacasereport AT qibaozhou venetoclaxcombinedwithatrashowspromisingtherapeuticpotentialfortfgraravariantaplacasereport AT feihu venetoclaxcombinedwithatrashowspromisingtherapeuticpotentialfortfgraravariantaplacasereport |